Bristol Readies Abilify Sales Force For Major Depressive Disorder Push

Bristol-Myers Squibb has restructured its sales force to support the launch of its atypical antipsychotic Abilify as an adjunct treatment for adults with major depressive disorder, Worldwide Pharmaceuticals Chief Operating Officer Lamberto Andreotti said during the company's 2007 fourth-quarter earnings call Jan. 31